Everest Clinical Research, an Arlington Capital Partners portfolio company, announced on December 1 its acquisition of Brightech International.
Brightech will continue to be led by Dr. Tai Xie, the company’s CEO and founder, and the existing management team. Terms of the deal were not disclosed.
Founded in 2002, Brightech International is a contract research organization (CRO) that specializes in complex, value-add biostatistics, programming and clinical data management services. Like Everest, Brightech has built a reputation as a critical partner for some of the world’s largest pharmaceutical and biotech companies. In addition to its New Jersey headquarters, Brightech has an expanded global reach with a second office in Asia.
Everest Clinical Research is a full-service CRO providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology and medical device industries.
According to the LevinPro HC database, this marks the 38th CRO transaction of 2022 and the eighth of the fourth quarter.
